FDAMA In Action? ODE Shows Progress On IDE Supplements, Five-Day Notice
This article was originally published in The Gray Sheet
Executive Summary
The Center for Devices and Radiological Health is addressing industry concerns over FDA's handling of increasing numbers of investigational device exemption supplements and use of the agency's five-day notice program for clinical trial changes
You may also be interested in...
FDA Should Cite Regulatory Imperative When Narrowing 510(k) Claims – Cook
FDA should consult with a three-person "supervisory" panel in deciding whether to narrow a proposed indication statement for 510(k) devices, Cook Group, Inc. suggests in March 4 comments to HHS Secretary Thompson's regulatory reform advisory committee
Sponsor-Investigator Trials Provide Avenue For Firms To Expand Device Uses
Physician studies of W.L. Gore's Helex septal occluder, used in the closure of atrial septal defects, demonstrate that the device can also close patent foramen ovale (PFO) for prophylaxis of recurrent paradoxical embolism and embolic stroke
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.